TITLE

CERUS/BAXTER REPORT GOOD RESULTS FOR EUROPEAN PHASE 3 TRIAL

PUB. DATE
October 2000
SOURCE
Worldwide Biotech;Oct2000, Vol. 12 Issue 10, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Announces the results of Cerus Corporation and Baxter Healthcare Corporation's European Phase 3 clinical trial of the Intercept Platelet System.
ACCESSION #
3635171

 

Related Articles

  • CLINIC ROUNDUP.  // BioWorld Today;2/10/2010, Vol. 21 Issue 27, p4 

    This section offers news briefs on clinical trials. The primary endpoint has been achieved in the Phase I trial of red blood cells treated with the intercept Blood System from Cerus Corp. Dosing has been completed by Palatin Technologies Inc. in the first cohort in the company's blood pressure...

  • CLINIC ROUNDUP.  // BioWorld Today;6/10/2008, Vol. 19 Issue 112, p8 

    This section offers news briefs on clinical trials. Positive safety and efficacy results were obtained by Achillion Pharmaceuticals Inc. from its Phase 1 trial studying elvucitabine in patients infected with human immunodeficiency virus (HIV). Majority of patients with untreated follicular...

  • Product Briefs.  // Medical Device Daily;12/14/2012, Vol. 16 Issue 242, p8 

    This section offers news briefs on medical devices. The first patient has enrolled for a study involving the polymer-free drug-coated stent from Biosensors International of Singapore called BioFreedom targeted at patients at high risk of bleeding. The U.S. Food and Drug Administration (FDA) has...

  • CERUS REPORTS NET LOSS OF $9.2 MILLION FOR 3RD. QTR.  // Biotech Financial Reports;Dec2000, p2 

    Reports the net loss of Cerus Corporation in Concord, California for the third quarter of the year 2000. Comparison with the net loss for the same quarter in the year 1999; Factors attributed for the net loss increase; List of developments within the company.

  • Cerus to Present at the Cowen and Company 32nd Annual Healthcare Conference on March 7 2012.  // Biomedical Market Newsletter;3/7/2012, Vol. 21, p1 

    The article informs that the Cowen & Co. annual healthcare conference will be held on March 7, 2012 in Boston, Massachusetts will feature Cerus Corp.

  • CERUS REPORTS THIRD QUARTER NET LOSS OF $12.7 MILLION.  // Biotech Financial Reports;Dec2001, p2 

    Announces the net loss of Cerus Corp. for the third quarter of 2001 in Concord, California. Impact of expanded research and development activities; Success in the clinical trials of the INTERCEPT platelet and plasma programs; Partnership with Baxter Healthcare Corp.

  • technology TODAY. Pierce, Alan // Tech Directions;Feb2003, Vol. 62 Issue 7, p13 

    Presents information on Helinx INTERCEPT Blood System, a blood cleansing technology process that deactivates pathogens in blood components developed by Cerus Corp. Reason for the need of handling human blood as a bio-hazardous material; Health aspects of blood transfusion; Action taken by...

  • Financings Roundup.  // BioWorld Today;4/7/2010, Vol. 21 Issue 66, p3 

    The article reports on the 10 million U.S. dollars growth capital credit facility secured by Cerus Corp. from Oxford Finance Corp. in April 2010.

  • Cerus to Release 1st Qtr 2012 Results on May 1 2012.  // Biomedical Market Newsletter;4/14/2012, Vol. 21, p1 

    The article offers information on a conference call to be hosted by Cerus Corp. on May 1, 2012 in which it will release its financial results for the first quarter of 2012.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics